Ingenious pH-sensitive dextran/mesoporous silica nanoparticles based drug delivery systems for controlled intracellular drug release

Zhang, Min; Liu, Jia; Kuang, Ying; Li, Qilin; Zheng, Di‐Wei; Song, Qiongfang; Chen, Hui; Chen, Xueqin; Xu, Yanglin; Li, Cao; Jiang, Bingbing

doi:10.1016/j.ijbiomac.2017.01.136

Cited by 66 publications

(18 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…pH-responsive nanoparticles have also been developed by conjugating nanocarriers with acid-labile linkage such as hydrazone [ 35 , 36 ], orthoester [ 37 , 38 ], imine [ 39 , 40 ], phosphoramidate [ 41 ], whose hydrolysis ensures rapid the release of the drug. Liao et al [ 42 ] have reported the synthesis of tumor targeting and pH-responsive nanoparticles for the enhanced delivery of DOX.…”

Section: Targeting Of Common Attributes Of Tmementioning

confidence: 99%

Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications

2018

View full text Add to dashboard Cite

BackgroundCancer is one of the deadliest threats to human health. Abnormal physiochemical conditions and dysregulated biosynthetic intermediates in the tumor microenvironment (TME) play a significant role in modulating cancer cells to evade or defend conventional anti-cancer therapy such as surgery, chemotherapy and radiotherapy. One of the most important challenges in the development of anti-tumor therapy is the successful delivery of therapeutic and imaging agents specifically to solid tumors.Main bodyThe recent progresses in development of TME responsive nanoparticles offers promising strategies for combating cancer by making use of the common attributes of tumor such as acidic and hypoxic microenvironments. In this review, we discussed the prominent strategies utilized in the development of tumor microenvironment-responsive nanoparticles and mode of release of therapeutic cargo.ConclusionTumor microenvironment-responsive nanoparticles offers a universal approach for anti-cancer therapy.

show abstract

Section: Targeting Of Common Attributes Of Tmementioning

confidence: 99%

Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications

2018

View full text Add to dashboard Cite

show abstract

“…The hydrazone linker gets rapidly cleaved under low pH conditions (which occur in endosomes, lysosomes and tumor tissue). Through the hydrazone linker, the drug was found to be released in the acidic tumor microenvironment or in the acidic organelles after cellular uptake by endocytosis [70][71][72][73][74][75]. Some more sleuthed polymer-drug conjugates containing hydrazone linkages are HPMA-DOX, PEG-DOX [76,77], PEG-epirubicin [78] and PEG-PTXL [79].…”

Section: Polymer-drug Conjugate (A) Dendrimers or Dendriticmentioning

confidence: 99%

Untitled

2020

ANN

View full text Add to dashboard Cite

Emergence of various nanoscale drug carrier platforms as Drug Delivery Systems (DDS) has revolutionized the field of medicine. Nonetheless, the side-effects due to non-specific distribution of anticancer therapeutics in normal, healthy tissues remains to be a prime pitfall in curing cancers. Therefore, to achieve a better therapeutic efficacy, the use of a target-specific delivery, combined with a stimuli-responsive nanocarrier system, particularly pH-sensitive nanosystems offer an attractive strategy. Targeted drug delivery through pH-sensitive nanosystems offer the potential to enhance the therapeutic index of anticancer agents, either by increasing the drug concentration in tumor cells and/or by decreasing the exposure in normal host tissues. Therefore, nanoscale-based drug delivery through pH-sensitive nanosystems seem to be a boon for treating gynaecological cancers (as well as other cancers) without side-effects or with least harm to normal healthy tissues.

show abstract

“…These linkers are cleaved in acidic conditions, triggering the release of the cargo from the carrier. Acetal bonds,50–52 hydrazine bonds,53–55 hydrazone bonds56,57 or ester bonds58,59 are some examples that have been used worldwide. In a study carried out by Ze-Yong Li et al, DOX was conjugated to MSPs using hydrazine bonds 60.…”

Section: Introductionmentioning

confidence: 99%

<p>Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles</p>

Iturrioz-Rodríguez¹,

Correa‐Duarte²,

Fanarraga³

2019

IJN

117

View full text Add to dashboard Cite

The implementation of nanotechnology in medicine has opened new research horizons particularly in the field of therapeutic delivery. Mesoporous silica particles have emerged as biocompatible drug delivery systems with an enormous potential in the treatment of cancer among many other pathologies. In this review, we focus on the unique properties of these particles as chemotherapy delivery carriers. Here, we summarize the general characteristics of these nanomaterials – including their physicochemical properties and customizable surfaces – different stimuli that can be used to trigger targeted drug release, biocompatibility and finally, the drawbacks of these types of nanomaterials, highlighting some of the most important features of mesoporous silica nanoparticles in drug delivery.

show abstract

Ingenious pH-sensitive dextran/mesoporous silica nanoparticles based drug delivery systems for controlled intracellular drug release

Cited by 66 publications

References 46 publications

Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications

Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications

Untitled

<p>Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles</p>

Contact Info

Product

Resources

About